Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches Post published:August 5, 2025 Post category:Analysis/Interviews/News/Pα+
Germany Establishes EU’s First Psilocybin Compassionate Access Program Post published:July 31, 2025 Post category:Analysis/News
Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2) Post published:July 29, 2025 Post category:Analysis/News
Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1) Post published:July 23, 2025 Post category:Analysis/News/Pα+
Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model Post published:July 1, 2025 Post category:Analysis/News/Pα+
Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study Post published:July 1, 2025 Post category:Analysis/News
Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout Post published:June 28, 2025 Post category:Analysis/News/Pα+
Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results Post published:June 25, 2025 Post category:Analysis/News/Pα+